Stem Cell Clinic

$150 Million Gift Takes Stem Cell Research to New Heights – University of California San Diego

From left, T. Denny Sanford, Catriona Jamieson, MD, PhD, and Chancellor Pradeep K. Khosla celebrate the establishment of the UC San Diego Sanford Stem Cell Institute, made possible by a historic gift from Sanford.

Noted businessman and philanthropist T. Denny Sanford has committed $150 million in new funding to expand and, in some ways, quite literally launch stem cell research and regenerative medicine at University of California San Diego into new spaces and endeavors.

The gift will fund the new UC San Diego Sanford Stem Cell Institute and builds upon a $100 million gift in 2013 from Sanford that boldly established UC San Diego as a leader in developing and delivering the therapeutic promise of human stem cells special cells with the ability to develop into many different cell types and which, when modified and repurposed, have the potential to treat, remedy or cure a vast array of conditions and diseases.

Dennys previous generosity spurred discoveries in stem cell research and medicine at UC San Diego that are already benefiting countless patients around the world, said Chancellor Pradeep K. Khosla. His most recent gift adds to our portfolio of stem cell research conducted in Earths orbit that will help us better understand the progression of cancer cells and aging.

Sanfords gift to establish the Sanford Stem Cell Institute is the largest single gift to UC San Diego. This investment enables the team to dream beyond what is possible, said Sanford. The sky is no longer the limit.

In addition to his investment to create the Sanford Stem Cell Clinical Center at UC San Diego Health in 2013, Sanford established the T. Denny Sanford Institute for Empathy and Compassion in 2019, which focuses on research into the neurological basis of compassion, with application toward developing compassion and empathy-focused training for future generations of medical professionals. He also recently made a $5 million gift to support the Epstein Family Alzheimers Research Collaboration, a partnership between UC San Diego and the University of Southern California to spark new collaborative efforts to discover effective therapies for Alzheimers disease.

Sanford was also honorary co-chair of the Campaign for UC San Diego, which concluded in June 2022 having raised more than $3 billion exceeding its initial $2 billion goal. He was honored as a recipient of the 2014 Chancellors Medal, one of the universitys highest honors, in recognition of his exceptional service in support of the campus mission.

Stem cell research will be conducted in a laboratory bay located aboard the International Space Station, pictured here, in low-Earth orbit. Credit: NASA

The new UC San Diego Sanford Stem Cell Institute, under the direction of Catriona Jamieson, MD, PhD, Koman Family Presidential Endowed Chair in Cancer Research in the UC San Diego School of Medicine, will continue three existing stem cell programs at UC San Diego with three new programs.

The new programs to be established with Sanfords gift include:

Existing stem cell programs at UC San Diego in the Sanford Stem Cell Institute include:

We are thrilled to announce the establishment of the UC San Diego Sanford Stem Cell Institute with Denny Sanfords generous support, said Jamieson. This will allow us to keep pace with the growing need for regenerative and stem-cell based therapies and accelerate translational stem cell research and discoveries that will transform human health for years to come.

With three new programs established as part of the Sanford Stem Cell Institute, a key focus of the institute will be leveraging space as a new frontier for stem cell science. Exposure to radiation and microgravity in low-Earth orbit can simulate and speed up aging in stem cells, as well as their transformation into cancer cells. Space-related research may have applications that create better treatments for various cancers and diseases on earth, including blood cancers, as well as neurodegenerative diseases such as Alzheimers and Parkinsons.

To fuel sustained research and education in this promising area, Sanfords gift will establish the Sanford Stem Cell Institute STELLAR Endowed Chair in Regenerative Medicine, the Sanford Stem Cell Institute Endowed STELLAR Exploration Faculty Scholars and Fellows Fund, and the Sanford Stem Cell Institute STELLAR Exploration Discovery Fund.

UC San Diego already has expanded its research capacity in stem cell science to space efforts that will be further amplified with the recent gift.

In late 2021, UC San Diego worked with NASA, Space Tango and the JM Foundation to launch stem cells into space aboard a SpaceX Falcon 9 rocket to study stress-induced aging and how stem cells and their progeny transform into pre-cancer and cancer stem cells associated with leukemia and other blood cancers.

Allyson Muotri, PhD, with human organoid samples

In 2019, Alysson Muotri, PhD, professor of pediatrics and cellular and molecular medicine, and colleagues sent a payload of stem cell-derived human brain organoids to the International Space Station (ISS) orbiting almost 250 miles above Earth to study how these masses of cells organize into the beginnings of a functional brain in microgravity. The first-ever project of its type was dedicated to Sanford, a longtime supporter of Muotris work and others.

When I was designing these experiments, I realized how innovative and cutting edge they were, said Muotri. I thought Denny would be proud of this project, and that I should dedicate this first mission to him. Denny has been a cheerleader for the stem cell community. He is pushing all of us to speed discovery and translate it to help millions of people who suffer from different conditions that could be treated with stem cell-based therapies.

Since its inception in 2013, the Sanford Stem Cell Clinical Center at UC San Diego has yielded a three-fold return on investment by obtaining more than $312 million in funding, including $253.6 million in grants, $15.8 million in clinical trial contracts, $2.7 million in Advanced Cell Therapy Lab (ACTL) service charges and more than $40.2 million in philanthropy all with the goal of discovering new treatments to benefit patients.

Key successes include new pharmaceutical treatments Fedratinib, which was approved by the FDA for the treatment of myelofibrosis in 2019, and Glasdegib, FDA approved for acute myeloid leukemia in 2018.

Meanwhile, clinical trials are ongoing for Cirmtuzumab, a monoclonal antibody-based drug developed by Thomas Kipps, MD, PhD, Distinguished Professor of Medicine and deputy director of research at Moores Cancer Center at UC San Diego Health, and colleagues. Cirmtuzumab targets cancer stem cells and is being tested, alone and in combination with other drugs, to treat chronic lymphocytic leukemia and other blood cancers.

Stem cell research at UC San Diego has been a substantial beneficiary of the California Institute for Regenerative Medicine (CIRM), the states stem cell agency, created in 2004 with the approval of Proposition 71. UC San Diego researchers have garnered 116 awards totaling more than $227 million. Cirmtuzumab is named as a nod to CIRM and its support. In 2020, California voters passed Proposition 14 to continue CIRM operations and funding.

Scott LaFee 858-249-0431 .(JavaScript must be enabled to view this email address)

Jade Griffin 858-761-5456 .(JavaScript must be enabled to view this email address)

See the original post:
$150 Million Gift Takes Stem Cell Research to New Heights - University of California San Diego

Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials…

James SL, Theadom A, Ellenbogen RG, Bannick MS, Montjoy-Venning W, Lucchesi LR, et al. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 19902016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):5687.

Article Google Scholar

Flack JA, Sharma KD, Xie JY. Delving into the recent advancements of spinal cord injury treatment: a review of recent progress. Neural Regen Res. 2022;17(2):283.

PubMed Article Google Scholar

Mansoori N, Bansil R, Sinha S. Current status of spinal cord regenerative therapies: a review. Indian J Neurosurg. 2016;5(01):0039.

Article Google Scholar

Ashammakhi N, Kim H-J, Ehsanipour A, Bierman RD, Kaarela O, Xue C, et al. Regenerative therapies for spinal cord injury. Tissue Eng Part B Rev. 2019;25(6):47191.

PubMed PubMed Central Article Google Scholar

Ramer LM, Ramer MS, Bradbury EJ. Restoring function after spinal cord injury: towards clinical translation of experimental strategies. Lancet Neurol. 2014;13(12):124156.

PubMed Article Google Scholar

Courtine G, Sofroniew MV. Spinal cord repair: advances in biology and technology. Nat Med. 2019;25(6):898908.

CAS PubMed Article Google Scholar

Assinck P, Duncan GJ, Hilton BJ, Plemel JR, Tetzlaff W. Cell transplantation therapy for spinal cord injury. Nat Neurosci. 2017;20(5):63747.

CAS PubMed Article Google Scholar

De Luca M, Aiuti A, Cossu G, Parmar M, Pellegrini G, Robey PG. Advances in stem cell research and therapeutic development. Nat Cell Biol. 2019;21(7):80111.

PubMed Article CAS Google Scholar

Chhabra HS, Sarda K, Jotwani G, Gourie-Devi M, Kaptanoglu E, Charlifue S, et al. Stem cell/cellular interventions in human spinal cord injury: is it time to move from guidelines to regulations and legislations? Literature review and Spinal Cord Society position statement. Eur Spine J. 2019;28(8):183745.

PubMed Article Google Scholar

Shang Z, Wang R, Li D, Chen J, Zhang B, Wang M, et al. Spinal cord injury: a systematic review and network meta-analysis of therapeutic strategies based on 15 types of stem cells in animal models. Front Pharmacol. 2022;13:819861.

PubMed PubMed Central Article Google Scholar

Gabel BC, Curtis EI, Marsala M, Ciacci JD. A review of stem cell therapy for spinal cord injury: large animal models and the frontier in humans. World Neurosurg. 2017;98:43843.

PubMed Article Google Scholar

Tator CH. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery. 2006;59(5):95787.

PubMed Article Google Scholar

Cote DJ, Bredenoord AL, Smith TR, Ammirati M, Brennum J, Mendez I, et al. Ethical clinical translation of stem cell interventions for neurologic disease. Neurology. 2017;88(3):3228.

PubMed Article Google Scholar

Matsuda R, Yoshikawa M, Kimura H, Ouji Y, Nakase H, Nishimura F, et al. Cotransplantation of mouse embryonic stem cells and bone marrow stromal cells following spinal cord injury suppresses tumor development. Cell Transplant. 2009;18(1):3954.

PubMed Article Google Scholar

Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinsons disease. Proc Natl Acad Sci USA. 2008;105(15):585661.

CAS PubMed PubMed Central Article Google Scholar

Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell. 2011;144(3):43952.

CAS PubMed PubMed Central Article Google Scholar

Aly RM. Current state of stem cell-based therapies: an overview. Stem Cell Investig. 2020;7:1-10.

Cyranoski D. Japan to offer fast-track approval path for stem cell therapies. Nat Med. 2013;19(5):510.

CAS PubMed Article Google Scholar

Rosemann A, Vasen F, Bortz G. Global diversification in medicine regulation: insights from regenerative stem cell medicine. Sci Cult (Lond). 2019;28(2):22349.

Article Google Scholar

Tang QR, Xue H, Zhang Q, Guo Y, Xu H, Liu Y, et al. Evaluation of the clinical efficacy of stem cell transplantation in the treatment of spinal cord injury: a systematic review and meta-analysis. Cell Transplant. 2021;30:9636897211067804.

PubMed Article Google Scholar

Liu S, Zhang H, Wang H, Huang J, Yang Y, Li G, et al. A comparative study of different stem cell transplantation for spinal cord injury: a systematic review and network meta-analysis. World Neurosurg. 2022;159:e232e43.

PubMed Article Google Scholar

Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):2649.

PubMed Article Google Scholar

Abdelaziz OS, Marie A, Abbas M, Ibrahim M, Gabr H. Feasibility, safety, and efficacy of directly transplanting autologous adult bone marrow stem cells in patients with chronic traumatic dorsal cord injury: a pilot clinical study. Neurosurg Q. 2010;20(3):21626.

Article Google Scholar

Adel N, Gabr H, Hamdy S, Afifi L, Mahmoud H. Stem cell therapy in chronic spinal cord injuries. Egypt J Neurol Psychiat Neurosurg. 2009;46(2):46778.

Google Scholar

Albu S, Kumru H, Coll R, Vives J, Valls M, Benito-Penalva J, et al. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021;23(2):14656.

CAS PubMed Article Google Scholar

Al-Zoubi A, Jafar E, Jamous M, Al-Twal F, Al-Bakheet S, Zalloum M, et al. Transplantation of purified autologous leukapheresis-derived CD34+ and CD133+ stem cells for patients with chronic spinal cord injuries: long-term evaluation of safety and efficacy. Cell Transplant. 2014;23(1_suppl):2534.

Article Google Scholar

Amr SM, Gouda A, Koptan WT, Galal AA, Abdel-Fattah DS, Rashed LA, et al. Bridging defects in chronic spinal cord injury using peripheral nerve grafts combined with a chitosan-laminin scaffold and enhancing regeneration through them by co-transplantation with bone-marrow-derived mesenchymal stem cells: case series of 14 patients. J Spinal Cord Med. 2014;37(1):5471.

PubMed PubMed Central Article Google Scholar

Bhanot Y, Rao S, Ghosh D, Balaraju S, Radhika CR, Kumar KVS. Autologous mesenchymal stem cells in chronic spinal cord injury. Br J Neurosurg. 2011;25(4):51622.

PubMed Article Google Scholar

Bryukhovetskiy AS, Bryukhovetskiy IS. Effectiveness of repeated transplantations of hematopoietic stem cells in spinal cord injury. World J Transplant. 2015;5(3):110.

PubMed PubMed Central Article Google Scholar

Chen W, Zhang Y, Yang S, Sun J, Qiu H, Hu X, et al. NeuroRegen scaffolds combined with autologous bone marrow mononuclear cells for the repair of acute complete spinal cord injury: a 3-year clinical study. Cell Transplant. 2020;29:0963689720950637.

PubMed Central Google Scholar

Cheng H, Liu X, Hua R, Dai G, Wang X, Gao J, et al. Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury. J Transl Med. 2014;12(1):18.

CAS Article Google Scholar

Chernykh E, Stupak V, Muradov G, Sizikov MY, Shevela EY, Leplina OY, et al. Application of autologous bone marrow stem cells in the therapy of spinal cord injury patients. Bull Exp Biol Med. 2007;143(4):5437.

CAS PubMed Article Google Scholar

Chhabra H, Sarda K, Arora M, Sharawat R, Singh V, Nanda A, et al. Autologous bone marrow cell transplantation in acute spinal cord injuryan Indian pilot study. Spinal cord. 2016;54(1):5764.

CAS PubMed Article Google Scholar

Curtis E, Martin JR, Gabel B, Sidhu N, Rzesiewicz TK, Mandeville R, et al. A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell stem cell. 2018;22(6):94150 e6.

CAS PubMed Article Google Scholar

Dai G, Liu X, Zhang Z, Wang X, Li M, Cheng H, et al. Comparative analysis of curative effect of CT-guided stem cell transplantation and open surgical transplantation for sequelae of spinal cord injury. J Transl Med. 2013;11(1):110.

Article Google Scholar

Dai G, Liu X, Zhang Z, Yang Z, Dai Y, Xu R. Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury. Brain Res. 2013;1533:739.

CAS PubMed Article Google Scholar

Deda H, Inci M, Kreki A, Kayhan K, zgn E, stnsoy G, et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy. 2008;10(6):56574.

CAS PubMed Article Google Scholar

Deng W-S, Ma K, Liang B, Liu X-Y, Xu H-Y, Zhang J, et al. Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury. Neural Regen Res. 2020;15(9):1686.

PubMed PubMed Central Article Google Scholar

El-Kheir WA, Gabr H, Awad MR, Ghannam O, Barakat Y, Farghali HA, et al. Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. Cell Transplant. 2014;23(6):72945.

PubMed Article Google Scholar

Geffner L, Santacruz P, Izurieta M, Flor L, Maldonado B, Auad A, et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008;17(12):127793.

CAS PubMed Article Google Scholar

Ghobrial GM, Anderson KD, Dididze M, Martinez-Barrizonte J, Sunn GH, Gant KL, et al. Human neural stem cell transplantation in chronic cervical spinal cord injury: functional outcomes at 12 months in a phase II clinical trial. Neurosurgery. 2017;64(CN_suppl_1):8791.

PubMed Article Google Scholar

Goni VG, Chhabra R, Gupta A, Marwaha N, Dhillon MS, Pebam S, et al. Safety profile, feasibility and early clinical outcome of cotransplantation of olfactory mucosa and bone marrow stem cells in chronic spinal cord injury patients. Asian Spine J. 2014;8(4):484.

PubMed PubMed Central Article Google Scholar

Hammadi AA, Andolina Marino SF. Clinical response of 277 patients with spinal cord injury to stem cell therapy in Iraq. Int J Stem Cells. 2012;5(1):76.

PubMed PubMed Central Article Google Scholar

Hur JW, Cho T-H, Park D-H, Lee J-B, Park J-Y, Chung Y-G. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial. J Spinal Cord Med. 2016;39(6):65564.

PubMed PubMed Central Article Google Scholar

Jeon SR, Park JH, Lee JH, Kim DY, Kim HS, Sung IY, et al. Treatment of spinal cord injury with bone marrow-derived, cultured autologous mesenchymal stem cells. Tissue Eng Regen Med. 2010;7(3):31622.

Google Scholar

Jiang P-C, Xiong W-P, Wang G, Ma C, Yao W-Q, Kendell SF, et al. A clinical trial report of autologous bone marrow-derived mesenchymal stem cell transplantation in patients with spinal cord injury. Exp Ther Med. 2013;6(1):1406.

PubMed PubMed Central Article Google Scholar

Kakabadze Z, Kipshidze N, Mardaleishvili K, Chutkerashvili G, Chelishvili I, Harders A, et al. Phase 1 trial of autologous bone marrow stem cell transplantation in patients with spinal cord injury. Stem Cells Int. 2016;2016:6768274.

PubMed PubMed Central Article CAS Google Scholar

Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, Eskandary H. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg. 2012;114(7):9359.

PubMed Article Google Scholar

Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data. Exp Clin Transplant. 2009;7(4):2418.

PubMed Google Scholar

Larocca TF, Macdo CT, de Freitas Souza BS, Andrade-Souza YM, Villarreal CF, Matos AC, et al. Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study. Cytotherapy. 2017;19(10):118996.

PubMed Article Google Scholar

Levi AD, Anderson KD, Okonkwo DO, Park P, Bryce TN, Kurpad SN, et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma. 2019;36(6):891902.

Originally posted here:
Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials...

IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the…

IMAC Holdings, Inc.

BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (IMAC or the Company), today announces it has completed the third cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinsons disease.

The third cohort consists of five patients with bradykinesia due to Parkinsons disease receiving an intravenous infusion of a high concentration stem cell treatment. The third and final cohort of the Phase 1 clinical trial was completed on Tuesday, September 6, 2022.

About IMACs Phase 1 Clinical Trial

The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, is being conducted at three of IMACs clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial is divided into three groups: 1) five patients with bradykinesia due to Parkinsons disease received a low concentration dose, intravenous infusion of stem cells, 2) five received a medium concentration intravenous dose, 3) and five received a high concentration intravenous dose. All groups will be subsequently tracked for 12 months. IMACs medical doctors and physical therapists at the clinical sites have been trained to administer the treatment and manage the therapy. Ricardo Knight, M.D., M.B.A., who is medical director of the IMAC Regeneration Center of Chicago, is the trials principal investigator.

The Institute of Regenerative and Cellular Medicine serves as the trials independent investigational review board, while Regenerative Outcomes provides management of the study. Further details of the trial can be found at clinicaltrials.gov.

About Bradykinesia Due to Parkinsons Disease

In addition to unusually slow movements and reflexes, bradykinesia may lead to limited ability to lift arms and legs, reduced facial expressions, rigid muscle tone, a shuffling walk, and difficulty with repetitive motion tasks, self-care, and daily activities. Parkinsons disease is the typical culprit of bradykinesia, and as it progresses through its stages, a persons ability to move and respond declines.

Story continues

According to Zion Market Research, the global Parkinsons disease therapeutics market was $2.61 billion in 2018 and is expected to grow to $5.28 billion by 2025. The Parkinsons Disease Foundation estimates that nearly 10 million people are suffering from Parkinsons disease, and almost 60,000 new cases are reported annually in the U.S.

About IMAC Holdings, Inc.

IMAC Holdingsowns and manages health and wellness centers that deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.IMACis comprised of three business segments: outpatient medical centers, The Back Space, and a clinical research division. With treatments to address both young and aging populations,IMAC Holdingsowns or manages outpatient medical clinics that deliver regenerative rehabilitation services as a minimally invasive approach to acute and chronic musculoskeletal and neurological health problems. IMACs The Back Company retail spinal health and wellness treatment centers deliver chiropractic care within Walmart locations. IMACs research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinsons disease. For more information visitwww.imacholdings.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe

lfristoe@imacrc.com

See the rest here:
IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the...

Top 3 grants in regenerative medicine: July 2022 – RegMedNet

This months top grants in regenerative medicine, sourced from Dimensions, includes projects on: a novel platform to enhance single cell interrogation of nervous system development, human endothelial cell regulation of ossification and the development of a dynamic double network hydrogel for generating pancreatic organoids from induced pluripotent stem cells.

This project aims to investigate a strategy, which utilizes novel spatial transcriptomics approaches, integrated multiplexed RNA/protein detection and visualization and computational algorithms to identify and map molecular markers of the preganglionic neurons in the ventral spinal cord and progenitor cell populations of the sympathetic ganglia. If successful, the approach could provide a foundation for basic research of peripheral nervous system birth defects and repair using stem cell-based therapies, as well as future studies of neuroblastoma initiation.

Funding amount:US$206,000

Funding period: 8 August 2022 31 July 2024

Funder:Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Research organization:Stowers Institute for Medical Research (MO, USA)

Read more

Over one million patients undergo bone repair procedures in the USA annually, with autologous bone grafting remaining the preferred treatment for bone defects. The development of therapies that exploit the osteogenic potential of bone marrow-derived mesenchymal stem cells (bm-MSCs) has been limited due to limited understanding of the regulatory mechanisms of in vivo bm-MSC osteogenesis. Previous research from the group showed that the osteogenic potential of bm-MSCs is dependent on sustained proximity to endothelial cells. The goal of the present study is to elucidate the cellular and molecular mechanisms by which endothelial cells regulate the osteogenic differentiation of bm-MSCs and develop a foundation of knowledge upon which to build therapeutic strategies for bone regeneration utilizing autologous bm-MSCs.

Funding amount:US$442,000

Funding period: 10 August 2022 31 May 2027

Funder:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Research organization:Boston Childrens Hospital (MA, USA)

Read more

Human induced pluripotent stem cells provide a valuable source of cells for basic research and translational applications. While there have been advances in lineage-specific differentiation of human induced pluripotent stem cells, there remains limited understanding on the impact of matrix stiffness, viscoelasticity and integrin ligand presentation on the multi-stage development of exocrine pancreatic organoids. This research aims to define the influence of matrix properties on the generation of exocrine pancreatic organoids by developing a viscoelastic dynamic double network hydrogel platform with controllable matrix mechanical properties and biochemical motifs. This will advance the application of chemically defined matrices as xeno-free artificial stem cell niches for organoid growth and tissue regeneration applications.

Funding amount:US$468,000

Funding period: 1 August 2022 31 July 2026

Funder:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Research organization: Indiana University Purdue University Indianapolis (IA, USA)

Read more

Brought to you with support from:

View post:
Top 3 grants in regenerative medicine: July 2022 - RegMedNet

New Method Promises to Yield More Therapeutic T Cells – Medscape

Producing the T lymphocytes that are increasingly being used to fight cancer and other diseasesmay soon be faster and more efficient, thanks to research being conducted at the University of British Columbia, in Vancouver, Canada.

Investigators found that adding the human proteins DLL4 and VCAM1 rather than using traditional animal products during a key cellular transition phase enhanced downstream output of progenitor T cells from pluripotent stem cells (PSCs) about 80-fold. The recombinant human proteins targeted the endothelial-to-hematopoietic (EHT) phase of development. If scaled up, the new process could substantially increase the availability and affordability of personalized T-cell immunotherapy.

Dr Yale Michaels

"Our goal is to be able to take cells from human donors, genetically modify and produce them in high numbers, and then store them in the freezer for off-the-shelf medicine," study author Yale S. Michaels, DPhil, postdoctoral fellow in biomedical engineering, told Medscape Medical News. "We think our technique will be ready for trials in humans within a couple of years."

The findings were published online August 24 in Science Advances.

Chimeric antigen receptor and engineered T-cell receptor T cells have demonstrated high clinical efficacy against some cancers. They also show promise for treating infection and immunologic disorders and for preventing transplant rejection, the authors write.

But sourcing these therapeutic cells from individual donors is costly and laborious, they add. Inter-donor variability and intra-donor heterogeneity make the production and quality control of personalized T-cell therapies challenging. The efficacy rate of this type of therapy is close to 50% for some cancers, but a new batch must be created for each treatment, and the cost is about half a million dollars each round, according to the researchers. Using PSCs to create immune cells in the laboratory could facilitate the derivation of hundreds of doses from a single cell.

Differentiating PSCs specifically into hematopoietic progenitors with T-cell potential remains difficult. "How to make the right type of cells from PSCs in the lab has been really challenging," said Michaels. "Previously, shepherd, or guide, cells from mouse cell lines or cow serum were used, but these shepherd cells produce so many different factors and components that it was hard to understand the minimum signals necessary to do the required job."

Michaels and his team believed that a pathway called notch signaling, which DLL4 and VCAM1 help to activate, would be important in the development of differentiated blood cells. As it turns out, VCAM1 cooperates with DLL4 to enhance the magnitude of notch signaling during the EHT culture phase. "We set out to understand the minimal signaling requirements for generating hematopoietic progenitors with T-cell potential from human PSCs," said Michaels.

The investigators coated lab Petri dishes with the DLL4 and VCAM1 proteins and added stem cells and growth media to foster the growth of blood cells with T-cell potential. "Production became faster and more efficient. As an added advantage, without the use of animal products, manufacturing can be done in a quality-controlled way that is easy to replicate and will make it suitable for clinical use," said Michaels.

Unexpectedly, the investigators also found that VCAM1 promoted inflammatory-responsive gene expression in hematopoietic stem cells. Studies in zebrafish and mice have shown that inflammatory signals are important for the emergence of these cells, both upstream and downstream of the notch pathway, they note.

Offering an oncologist's perspective, Cassian Yee, MD, a professor of melanoma medical oncology and immunology at the University of Texas MD Anderson Cancer Center in Houston, agreed that ultimately, the goal is to prescribe off-the-shelf treatment with T cells designed for a given cancer type and stage. "The method described by Michaels et al is a significant step in that direction," he told Medscape. The technique "utilizes well-defined reagents that could likely be rendered clinical-grade compatible for ex vivo manufacturing and is able to produce a diverse T-cell repertoire." Yee was not involved in the current study.

Dr Cassian Yee

But many steps remain before that goal is reached, Yee cautioned. Among them are identifying and engineering T cells with the desired specificity, enriching and expanding them efficiently from a PSC-derived product with the desired intrinsic properties, and achieving scalability. "But I believe that ultimately, these issues are all addressable and this technology opens the door a little wider to that possibility," said Yee.

The research was funded by Notch Therapeutics, the Stem Cell Network Fueling Biotechnology Partnerships, the Canadian Institute for Health Research Foundation, and the Wellcome Leap Human Organs, Physiology, and Engineering program. Michaels is an inventor of patents relating to T-cell differentiation and consults for regenerative medicine companies, including Notch Therapeutics. Yee sits on the advisory boards of several cell therapy companies, but none are engaged in research relevant to his comments.

Sci Adv. Published online August 24. Full text

Diana Swift is a medical journalist based in Toronto. She can be reached at dianaswift@rogers.com.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Visit link:
New Method Promises to Yield More Therapeutic T Cells - Medscape

Stem Cell Therapy Approach On War Injury Patients – NewsPatrolling

Peshmerga Army Invites Dr Pradeep Mahajan To Addressed a treatment using Stem Cell Therapy on injured wounds

Mumbai: Stem cell therapy possesses both diagnostic and therapeutic potential. The use of stem cells for pain management can help with fast, safe, effective, and lasting results in terms of injuries. Dr. Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd conducted a session on the benefits of stem cell therapy to help the Peshmerga Army bounce back from serious injuries. Indian High Commissioner attended the meeting Consul general of India Subhash C. Kain attended a meeting with the commander in chief Houshmmad of Peshmerga & Major Dr. Dana A. Ali

Stem cells therapy can be used for the treatment of injuries where surgery does not heal wounds of skin muscles, tendons, bones, the sensory part, solid organs, nervous system and other skeleton muscle and pulmonary tissues , also it will look into radiation syndromes to treat using stem cells.

Stem cell therapy has been a boon for a large number of patients and is becoming increasingly popular. It is used to treat complex diseases without any complications. Stem cell therapy will not only yield positive results in common people but army men too. The Peshmerga forces have sacrificed a lot during the war against the ISIS terrorist group in the last decade to protect their country and the entire world from terrorist threats. Unfortunately, as a result of the war, besides thousands of Peshmerga have been martyred, more than 10,000 peshmergas have been injured critically. Some of them are fully healed, while others still need to be treated. To promptly tackle the need of the soldiers, Dr Pradeep Mahajan has been invited by the Ministry of Peshmerga, Kurdistan.

Dr Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd said, It was an honor to deliver a lecture on stem cell therapy for Peshmerga forces in Kurdistan. If there is war then there are going to be injuries. I briefed them about how revolutionary stem cell therapy can be a game changer for them when it comes to untreatable diseases. I respect the army men for their courage, spirit, and love towards the country. It was a proud moment for me to deliver a lecture for them. I hope to get more such opportunities in the near future and help the army men to overcome injuries and improve their quality of life.

It is a proud moment for the Indian Community to extend the high technology to improve the recovery of a war injury.

See original here:
Stem Cell Therapy Approach On War Injury Patients - NewsPatrolling

Cell Therapy And Acellular Therapy Market See Huge Growth for New Normal | Aegle Therapeutics Corp, ArunA Biomedical – Fighting Hawks Magazine -…

California (United States) Cell Therapy And Acellular Therapy Market research is an intelligence report with meticulous efforts to study the right and valuable information. The data that has been looked upon is done considering the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well-explained SWOT analysis, revenue share, and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

Some of the Top companies Influencing this Market include:

Aegle Therapeutics Corp, ArunA Biomedical, Capricor Therapeutics, Inc., Codiak BioSciences, Inc., Direct Biologics, LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine, Inc., Rion LLC, Stem Cell Medicine Ltd..

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists the restraints that are posing a threat to the global

Global Cell Therapy And Acellular Therapy Market Segmentation:

Market Segmentation: By Type

Cell Therapy Acellular Therapy

Market Segmentation: By Application

Cardiology Hepatology Neurology Gastroenterology Oncology

The report provides insights on the following pointers:

Market Penetration: Comprehensive data on the product portfolios of the top players in the Cell Therapy And Acellular Therapy market.

Product Development/Innovation: Detailed information about upcoming technologies, R&D activities, and market product debuts.

Competitive Assessment: An in-depth analysis of the markets top companies market strategies, as well as their geographic and business segments.

Market Development: Information on developing markets in their entirety. This study examines the market in several geographies for various segments.

Market Diversification: Extensive data on new goods, untapped geographies, recent advancements, and investment opportunities in the Cell Therapy And Acellular Therapy market.

Get Up to 30% Discount on the first purchase of this report @:

Global Cell Therapy And Acellular Therapy market Report Scope:

The cost analysis of the Global Cell Therapy And Acellular Therapy Market has been performed while considering manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy considered.

Key questions answered in this report:

Table of Contents

Global Cell Therapy And Acellular Therapy Market Research Report 2022 2029

Chapter 1 Cell Therapy And Acellular Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cell Therapy And Acellular Therapy Market Forecast

Buy Exclusive Report:

If you have any special requirements, please let us know, and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4157

Cell Therapy And Acellular Therapy, Cell Therapy And Acellular Therapy market, Cell Therapy And Acellular Therapy market research, Cell Therapy And Acellular Therapy market report, Cell Therapy And Acellular Therapy Market comprehensive report, Cell Therapy And Acellular Therapy market forecast, Cell Therapy And Acellular Therapy market growth, Cell Therapy And Acellular Therapy Market in Asia, Cell Therapy And Acellular Therapy Market in Australia, Cell Therapy And Acellular Therapy Market in Europe, Cell Therapy And Acellular Therapy Market in France, Cell Therapy And Acellular Therapy Market in Germany, Cell Therapy And Acellular Therapy Market comprehensive analysis, COVID 19 impact on Cell Therapy And Acellular Therapy market, Aegle Therapeutics Corp, ArunA Biomedical, Capricor Therapeutics, Inc., Codiak BioSciences, Inc., Direct Biologics, LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine, Inc., Rion LLC, Stem Cell Medicine Ltd.

Read more:
Cell Therapy And Acellular Therapy Market See Huge Growth for New Normal | Aegle Therapeutics Corp, ArunA Biomedical - Fighting Hawks Magazine -...

Global Cell Culture Market to Grow by 11.99% Annually Through 2029 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cell Culture Market Analysis by Product, by Application, by End User, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The global cell culture market size is valued to be USD 19.78 billion in 2021 and is anticipated to witness a CAGR of 11.99% during the forecast period. Growth in awareness regarding the advantages of cell culture-based vaccines is a key driver for the growth of the global cell culture market. Additionally, increase in demand for monoclonal antibodies and subsidy offered to cell-based research in the cell culture market is some of the other drivers propelling the market growth. Nevertheless, high cost of cell culture treatment and shortage of structure for cell-based research in emerging economies are expected to restrain the global market growth.

By Product

Based on product segment, the market is sub-segmented into consumables and equipment. In 2021, the consumables segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the recurrent purchase of consumables along with increasing subsidy for cell-based research. worldwide. Equipment segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing risk of pandemic and communicable diseases.

By Application

Based on application, the market is segmented into biopharmaceutical production, diagnostics, drug screening and development, stem cell research, tissue engineering & regenerative medicine, and other applications. In 2021, the biopharmaceutical production segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to growing governing sanctions for the manufacture of cell culture-based vaccines along with an increasing demand for monoclonal antibodies (mAbs) worldwide. Stem cell research segment is expected to grow at a profitable CAGR during the forecast period. This is attributed to the growth in advancements of proteomic gene expression and consequent growth of new vaccine and biopharmaceuticals globally.

By End User

Based on end user, the market is categorized into cell banks, pharmaceutical & biotechnology companies, academic & research institutes, and hospitals and diagnostic laboratories. In 2021, the pharmaceutical & biotechnology companies segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is due to the growth in application of single-use technologies along with the increase in number of regulatory sanctions for manufacturing of cell culture-based vaccines worldwide. The cell banks segment is anticipated to grow at a profitable CAGR during the forecast period, due to the rise in incidence of chronic diseases that have resulted in increase in cell biology & cytological studies.

Consumables

Bioreactor Accessories

Equipment

Supporting Equipment

Other Supporting Equipment

Single-Use Bioreactors

Storage Equipment

Cell Culture Market, By Application (Revenue, USD Billion, 2021-2029)

Biopharmaceutical Production

Cell Culture Market, By End User (Revenue, USD Billion, 2021-2029)

Cell Culture Market, By Region (Revenue, USD Billion, 2021-2029)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Key Topics Covered:

1. Research Methodology

2. Introduction: Cell Culture

3. Executive Summary

4. Market Dynamics

5. Market Environment Analysis

6. COVID-19 Impact Analysis: Cell Culture Market

7. Market Analysis by Product

8. Market Analysis by Application

9. Market Analysis by End User

10. Regional Market Analysis

11. North America Cell Culture Market

12. Europe Cell Culture Market

13. Asia Pacific Cell Culture Market

14. Latin America Cell Culture Market

15. MEA Cell Culture Market

16. Competitor Analysis

17. Company Profiles

18. Conclusion & Recommendations

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/g47hlz

Originally posted here:
Global Cell Culture Market to Grow by 11.99% Annually Through 2029 - ResearchAndMarkets.com - Business Wire

Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth – Yahoo…

Company Logo

Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2022" report has been added to ResearchAndMarkets.com's offering.

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The cargo contained within exosomes can offer prognostic information for a range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

Story continues

The Era of Exosomes

For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to credit exosomes for a range of promising traits.

To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.

Today the exosome industry is witnessing:

A surging number of scientific papers investigating exosomes and their applications

Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics

Swelling appetite among investors for exosome technology

An increasingly competitive IP environment

A diverse range of co-development partnerships

Proliferating numbers of exosome competitors in all major life science markets worldwide

This global strategic report about the exosome industry reveals:

The clinical pipeline for exosome therapeutics

Clinical trial activity by type, region, phase, and sponsor

Exosome industry events, including M&A activity, financing events, and IPOs

Strategic partnerships and co-development agreements

Competitors composing the global marketplace, including core technologies and products under development

Market size determinations by market segment, with forecasts through 2030

Exosome industry trends, competitive opportunities, and future directions.

Key Topics Covered:

1. REPORT OVERVIEW

2. EXOSOMES: AN OVERVIEW

3. EXOSOME ENGINEERING: THE NEW PLATFORM

4. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE

5. EXOSOME RESEARCH

6. COMMERCIALLY AVAILABLE EXOSOME RESEARCH TOOLS

7. SCIENTIFIC PUBLICATIONS IN EXOSOMES

8. EXOSOME PATENT LANDSCAPE

9. EXOSOMES: CLINICAL TRIAL LANDSCAPE

10. CURRENT STATUS OF EXOSOME MANUFACTURING

11. EXOSOME ISOLATION APPROACHES

12. DIAGNOSTIC APPLICATIONS OF EXOSOMES

13. THERAPEUTC APPLICATIONS OF EXOSOMES

14. APPLICATION OF EXOSOMES IN VACCINE DEVELOPMENT

15. CURRENT STATUS OF EXOSOME INDUSTRY

16. EXOSOME MARKET ANALYSIS

17. PROFILES OF EXOSOME MARKET COMPETITORS Companies Mentioned

101 Bio

AB

Abbexa, Ltd.

Abnova

Acquisition by Therillia

Adipomics, Inc.

Aegle Therapeutics

Aethlon Medical, Inc.

AgeX Therapeutics

Ambiotech

AmnioStem Stroke Therapy

AmniWrap

AMS Biotechnology, Ltd. (AMSBIO)

Anjarium Biosciences

Anjarium's Hybridosome Platform

Antibodies-Online GmbH

Aposcience AG

Aruna Bio

Avalon GloboCare Corp.

Avalon's Core Platforms

Aviva Systems Biology

AZ Platform

Azymus Therapeutics

Beckman Coulter Life Sciences

Bio-Techne

BioCat GmbH

BioDrone Technology

BioFluidica

Biological Dynamics, Inc.

Biorbyt, Ltd.

BioRegenerative Sciences, Inc.

BioVision, Inc.

BrainStorm Cell Therapeutics

BreStem Therapeutics, Inc.

Capricor Therapeutics

Carmine Therapeutics

CBD-Loaded Exosomes

CCT-

CD Bioparticles

Cell Care Therapeutics

Cell Factory BVBA/Esperite NV

Cell Guidance Systems, Ltd.

Cellarcus Biosciences, Inc.

Cevaris Plexaris

Ciola

CK-Exogene

Clara Biotech

Codiak Biosciences

Coya Therapeutics, Inc.

Craif, Inc.

Creative Bioarray

Creative Biolabs

Creative Medical Technology Holdings

Creative Proteomics

CreativeBiostructure

Curexsys GmbH

CUSABIO TECHNOLOGY LLC

Original post:
Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth - Yahoo...